The confluence of China’s rapidly rising biotech prowess and US policy decisions that hamper the industry is a cause for ...

Eli Lilly is predicting strong sales and profit growth in 2026, seemingly shrugging off the pricing pressure that weighed ...

Looking ahead to 2026, Doustdar said Novo Nordisk had high expectations for the potential launches of new incretin ...

The loss of market exclusivity for a trio of big-selling drugs in the last quarter of 2025 dragged down Novartis sales, but ...

"The government has claimed that the deal will only cost around £1 billion per year, but the UK's new commitment to double ...

When it comes to developing new cancer treatments, too often teams are focused on finding the treatment that most effectively kills tumours. But that’s only part of the goal, argues Immuneering CEO ...

There’s no doubt that large language models and generative AI tools have taken the world by storm. Their ability to create, ...

Luke Miels' first financial results since taking over as chief executive of GSK revealed a jump in sales and profits, fuelled by HIV, cancer and respiratory medicines.

ICH E6 (R3) introduces a dedicated section on data governance, reflecting the increasing complexity of data sources and ...

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Lisa Sims, executive director of learning strategy & ...

Wave Life Sciences has lost GSK as the partner for its RNA-editing drug for alpha-1 antitrypsin deficiency (AATD), just over ...

AstraZeneca is already deeply embedded in China's pharma sector, and is hungry for more, pledging $15 billion to an ...